- CA$149.21m
- CA$145.14m
- CA$0.07m
2019 March 31st | 2020 March 31st | C2021 March 31st | R2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.002 | 0.347 | 0.073 |
Cost of Revenue | |||||
Gross Profit | — | — | -0.194 | -0.03 | -0.78 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2.44 | 1.68 | 4.32 | 32.6 | 15 |
Operating Profit | -2.44 | -1.68 | -4.31 | -32.2 | -15 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.43 | -1.54 | -3.87 | -31.7 | -14.4 |
Net Income After Taxes | -2.43 | -1.54 | -3.87 | -31.7 | -14.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.43 | -1.54 | -3.87 | -31.7 | -14.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.43 | -1.54 | -3.87 | -31.7 | -14.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.036 | -0.02 | -0.046 | -0.131 | -0.145 |